




EZEKIEL W. CULLEN
BUILDING

Cancer Therapeutics Course
Professor Scott R. Gilbertson
August 18, 2021

UNIVERSITY *of* **HOUSTON**

Drug Discovery Pipeline



Validation and Evaluation of Hits

Validate structure and purity by independent synthesis.

Purchase from another source is often not that.

Evaluate structure for the ability to modify and optimize.

Drug likeness. Not necessarily Lipinski's rules but if molecule has poor solubility or stability things will be hard!



Synthetic tractability

Can someone get you the diverse structures you will need to advance the hit?

How we learned this the hard way!

Target: Separase


- Separase is a protease important for cell division, is overexpressed in over 60% of breast tumor specimens, and 50% of TNBC and 65% of Luminal B tumors. Separase overexpression strongly correlates with aneuploidy, high incidence of relapse, metastasis, and a lower 5-year overall survival rate. In mouse models, Separase overexpression has been shown to induce aneuploidy and mammary tumorigenesis.
- Our colleague developed a HTS assay for this enzyme.
- That screen was done in the *GCC* screening center.




C

	S:B	S:B Range (A : B)	S:N	S:N Range (A : B)	Z'	Z' Range (A : B)
Mean	10.54	(10.75 : 10.34)	46.35	(47.92 : 44.77)	0.55	(0.57 : 0.54)
σ	2.69	(3.06 : 3.03)	15.77	(20.38 : 18.70)	0.10	(0.12 : 0.12)


D



E



Lead Compound from HTS of Maybridge Library




Synthesis of the structure provided by Maybridge gave a molecule that was not stable and was the wrong color.



So the first issue was the structure provided by the company was incorrect. Another common problem can be impurities in the sample leading to activity that is not related to the expected structure.

Identification and Characterization of Separase Inhibitors (Sepins) for Cancer Therapy

Nenggang Zhang¹, Kathleen Scorsone¹, Gouqing Ge¹, Caterina C. Kaffes¹, Lacey E. Dobrolecki², Malini Mukherjee¹, Michael T. Lewis², Stacey Berg¹, Clifford C. Stephan³, and Debananda Pati¹

2014, Vol. 19(6) 878–889
© 2014 Society for Laboratory
Automation and Screening
DOI: 10.1177/1087057114520972
jbx.sagepub.com


Three Sites for Optimization



Issues to address

Nitro groups are generally not a good functional group for drugs.

They are converted to reactive molecules such as nitroso compounds.



Not a very drug like structure

Highly charged **cLogP -5.3** (Chemicalize.org)

May be an acceptor of nucleophiles (stability issue)

Moderate activity


Reaction Conditions Lead to Multiple Products with Some Substrates




Harsh chemistry
necessary to access the
molecule limits the
types of
pharmacophores that
can be attached.

Two products obtained

Modification of the Bromide Would Allow for the Synthesis of Version After the Problem Step




These side reactions have been one of the problems with this system.




Reoxidation of the reduced biproducts was not consistent


Replacement of the Nitro Group




Sepin 1.1




Sepin 1.2




Sepin 1.3



Sepin 1.4




Sepin 1.5




Every version without the nitro group is less active
Both electron withdrawing and H-bond acceptor groups


Miscellaneous Changes




Sepin 1.1




Sepin 1.43




Sepin 1.44




Sepin 1.45




Sepin 1.46




Sepin 1.47




Sepin 1.48




Sepin 1.49




Final Nail in the Coffin



This site readily reacts with nucleophiles



Summary to date



Acknowledgements

- Dr. Ha Do
- Silviya Demerzhan
- Dr. Debananda Pati
- Dr. Anton Agarkov
- Dr. Zhang Nenggang



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

UNIVERSITY of
HOUSTON
DEPARTMENT OF CHEMISTRY